Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in Both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting

Media coverage

• Title	Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in Both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
  Media name/outlet	Impact Financial News
  Country/Territory	United Kingdom
  Date	30/09/24
  Persons	Mark Lebwohl